Takeda Agrees to Pony Up $2.3 Billion to Settle Actos Cases
Takeda Pharmaceutical Co. executives have agreed to pay more than $2.3 billion to resolve lawsuits accusing the company of hiding its Actos diabetes medicine’s cancer risks, three people familiar with the accord said.
Takeda directors still must vote on the deal, designed to resolve more than 8,000 suits, said the people, who asked not to be identified because they weren’t authorized to speak publicly about the settlement.
The accord would offer a payment of more than $287,000 per case to those who sign up for the settlement program while former Actos users whose injuries warrant more compensation can continue to litigate their claims, the people said.
Help employers find you! Check out all the jobs and post your resume.
Takeda directors still must vote on the deal, designed to resolve more than 8,000 suits, said the people, who asked not to be identified because they weren’t authorized to speak publicly about the settlement.
The accord would offer a payment of more than $287,000 per case to those who sign up for the settlement program while former Actos users whose injuries warrant more compensation can continue to litigate their claims, the people said.
Help employers find you! Check out all the jobs and post your resume.